Previous close | 0.6000 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 10.00 |
Expiry date | 2024-07-19 |
Day's range | 0.6000 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | 323 |
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.